Guided Self-Change Prevention Program for Alcohol Abuse in Adolescents in Educational Settings (PREVENALC)

July 27, 2024 updated by: Jose Luis Carballo Crespo, PhD, Universidad Miguel Hernandez de Elche

Prevention of Alcohol Abuse in Educational Settings (PRVENALC)

This study corresponds to a pretest-posttest randomized experimental design with two arms. Arm 1 includes Guided Self-Change program, and Arm 2 a psychoeducational program to promote healthy habits. This study aims to analyze the efficacy of a selective and indicated prevention program based on the Guided Self-Change model (GSC) in adolescent alcohol users between 16-18 years. Researchers hypothesize that implementation of GSC therapy will lead to a greater reduction of alcohol drinkers compare with the control condition, and will prevent alcohol abuse after 6 and 12 months.

Study Overview

Study Type

Interventional

Enrollment (Actual)

800

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alicante
      • Elche, Alicante, Spain, 03203
        • José Luis Carballo

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • 16-18 years old.
  • Having inform consent from parents
  • Report using alcohol at least once a month during the previous last three months

Exclusion Criteria:

  • Participants will be excluded if they refer being diagnosed with a severe mental disorder.
  • Have a severe medical illness that will limit participation
  • Being under treatment for a psychological of psychiatric problem.
  • Meet DSM criteria for Drug dependence to illegal drugs.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Guided Self-Change therapy
The GSC program follows a motivational cognitive-behavioral approach designed to minimize resistance in drug behavior changes, prevent relapse risk, and increase motivation to quit. The GSC consists of 5 weekly sessions of 50 minutes delivered in groups of 20-25 people.
Active Comparator: Psychoeducation program about healthy habits
The psychoeducational program will include talks about healthy habits such as physical activity, relaxation, and sleep hygiene. This intervention consists of 5 weekly sessions of 50 minutes delivered in groups of 20-25 people.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Alcohol use change
Time Frame: Change from baseline up to 5 weeks and two follow-ups at 6 and 12 months post intervention
Alcohol use will be assessed using the Timeline Follow-Back (Sobell & Sobell, 1992)
Change from baseline up to 5 weeks and two follow-ups at 6 and 12 months post intervention
Alcohol abuse
Time Frame: Change from baseline to week 5, and at 6 and 12 months post intervention.
Alcohol abuse will be assessed using the Rutgers Alcohol Problem Index (White & Labouvie, 1989). The global score ranges from 0 to 69, where higher scores represent greater level of alcohol-related problems.
Change from baseline to week 5, and at 6 and 12 months post intervention.
Alcohol dependence
Time Frame: Change from baseline to week 5, and at 6 and 12 months post intervention.
Alcohol dependence will be assessed with the Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (Grant et al., 2015).
Change from baseline to week 5, and at 6 and 12 months post intervention.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Drug use
Time Frame: Change from baseline to week 5, and at 6 and 12 months post intervention.
Assessed with the Drug History Questionnaire (Sobell et al., 1995).
Change from baseline to week 5, and at 6 and 12 months post intervention.
Impulsiveness
Time Frame: Change from baseline to week 5, and at 6 and 12 months post intervention.
Impulsiveness will be assessed with the Impulsive Behavior Scale (Cyders et al., 2014). The global score ranges from 20 to 80, where higher scores represent greater level of impulsivity.
Change from baseline to week 5, and at 6 and 12 months post intervention.
Sleep quality
Time Frame: Change from baseline to week 5, and at 6 and 12 months post intervention.
Sleep will be assessed with different sleep measures, such as the Brief version of the Pittsburgh Sleep Quality Index (Sancho-Domingo et al., 2021). The global score of the B-PSQI ranges from 0 to 15, where higher scores represent poor sleep quality.
Change from baseline to week 5, and at 6 and 12 months post intervention.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: José Luis Carballo, PhD, Miguel Hernández University of Elche

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 21, 2022

Primary Completion (Actual)

May 1, 2024

Study Completion (Actual)

May 15, 2024

Study Registration Dates

First Submitted

February 10, 2022

First Submitted That Met QC Criteria

March 10, 2022

First Posted (Actual)

March 16, 2022

Study Record Updates

Last Update Posted (Actual)

July 30, 2024

Last Update Submitted That Met QC Criteria

July 27, 2024

Last Verified

July 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • PID2019-110400RB-I00

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alcohol Abuse or Dependence

Clinical Trials on Guided Self-Change therapy (GSC)

Subscribe